Amarin Corporation PLC (NASDAQ:AMRN): 3 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $6.5 in Amarin Corporation PLC (NASDAQ:AMRN). However, the stock price could fluctuate by $ 3.28 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $10 price target with the lower price estimate is calculated at $4
Many analysts have stated their opinion on the company shares. Jefferies initiates coverage on Amarin Corporation PLC (NASDAQ:AMRN) . The global brokerage major announces a current price target of $3.5 per share. Analysts at the Jefferies have a current rating of Buy on the shares. The rating by the firm was issued on May 12, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Thero John F, CEO of Amarin Corp PlcUk, executed a transaction worth $34,250 on February 1, 2016. A total of 25,000 shares were purchased at an average price of $1.37. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Amarin Corporation PLC (NASDAQ:AMRN) : On Monday heightened volatility was witnessed in Amarin Corporation PLC (NASDAQ:AMRN) which led to swings in the share price. The stock opened for trading at $2.12 and hit $2.175 on the upside , eventually ending the session at $2.13, with a gain of 0.47% or 0.01 points. The heightened volatility saw the trading volume jump to 1,068,558 shares. The 52-week high of the share price is $2.65 and the company has a market cap of $394 million. The 52-week low of the share price is at $1.24 .
Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarins lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.